C A Duncan

700 total citations
13 papers, 601 citations indexed

About

C A Duncan is a scholar working on Pharmacology, Surgery and Oncology. According to data from OpenAlex, C A Duncan has authored 13 papers receiving a total of 601 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pharmacology, 4 papers in Surgery and 4 papers in Oncology. Recurrent topics in C A Duncan's work include Pharmacogenetics and Drug Metabolism (5 papers), Cancer, Lipids, and Metabolism (3 papers) and Lipoproteins and Cardiovascular Health (3 papers). C A Duncan is often cited by papers focused on Pharmacogenetics and Drug Metabolism (5 papers), Cancer, Lipids, and Metabolism (3 papers) and Lipoproteins and Cardiovascular Health (3 papers). C A Duncan collaborates with scholars based in United States. C A Duncan's co-authors include S. Vickers, D E Duggan, Avery Rosegay, Byron H. Arison, Harri G. Ramjit, Kamlesh P. Vyas, Michael S. Schwartz, P H Kari, Steven M. Pitzenberger and Shimoga R. Prakash and has published in prestigious journals such as Biochemical and Biophysical Research Communications, Drug Metabolism and Disposition and Xenobiotica.

In The Last Decade

C A Duncan

13 papers receiving 564 citations

Peers

C A Duncan

SURGE

PHARM

MB

CTM

ONCOL

P H Kari United States

Ronald J. Gerson United States

Ian Holmes United States

Lynn M. Gorham United States

Donald E. Slaughter United States

Karl-Fr. Sewing Germany

Toshio Kamei Japan

Michelle W. Kloss United States

D W Bilheimer United States

Jean‐Marie Pereillo France

P H Kari United States

C A Duncan

164 ×0.7

SURGE

144 ×0.8

PHARM

153 ×0.9

MB

70 ×0.5

CTM

79 ×0.7

ONCOL

Citations per year, relative to C A Duncan C A Duncan (= 1×) peers P H Kari

Countries citing papers authored by C A Duncan

Since Specialization

Citations

This map shows the geographic impact of C A Duncan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C A Duncan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C A Duncan more than expected).

Fields of papers citing papers by C A Duncan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C A Duncan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C A Duncan. The network helps show where C A Duncan may publish in the future.

Co-authorship network of co-authors of C A Duncan

This figure shows the co-authorship network connecting the top 25 collaborators of C A Duncan. A scholar is included among the top collaborators of C A Duncan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C A Duncan. C A Duncan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

1.

Vickers, S., Anthony D. Theoharides, Byron H. Arison, et al.. (1999). In Vitro and In Vivo Studies on the Metabolism of Tirofiban. Drug Metabolism and Disposition. 27(11). 1360–1366. 32 indexed citations

2.

Vickers, S., C A Duncan, Donald E. Slaughter, et al.. (1998). Metabolism of MK-499, a class III antiarrhythmic agent, in rats and dogs.. PubMed. 26(5). 388–95. 4 indexed citations

3.

Cheng, Hsien C., Michael S. Schwartz, S. Vickers, et al.. (1994). Metabolic disposition of simvastatin in patients with T-tube drainage.. Drug Metabolism and Disposition. 22(1). 139–142. 33 indexed citations

4.

Vickers, S., et al.. (1994). Disposition of MK-852, a fibrinogen receptor antagonist, in rats and dogs.. Drug Metabolism and Disposition. 22(4). 631–636. 3 indexed citations

5.

Vickers, S., C A Duncan, P H Kari, et al.. (1993). In vivo and in vitro metabolism studies on a class III antiarrhythmic agent.. Drug Metabolism and Disposition. 21(3). 467–473. 9 indexed citations

6.

Vickers, S. & C A Duncan. (1991). Studies on the metabolic inversion of the 6′ chiral center or simvastatin. Biochemical and Biophysical Research Communications. 181(3). 1508–1515. 3 indexed citations

7.

Vickers, S., C A Duncan, Kamlesh P. Vyas, et al.. (1990). In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase.. Drug Metabolism and Disposition. 18(4). 476–483. 136 indexed citations

8.

Vickers, S., et al.. (1990). Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug.. Drug Metabolism and Disposition. 18(2). 138–145. 217 indexed citations

9.

Duggan, D E, W.F. Bayne, Rita A. Halpin, et al.. (1989). The physiological disposition of lovastatin.. Drug Metabolism and Disposition. 17(2). 166–173. 102 indexed citations

10.

Vickers, S., C A Duncan, Harri G. Ramjit, et al.. (1985). Carnitine and glucuronic acid conjugates of pivalic acid. Xenobiotica. 15(6). 453–458. 36 indexed citations

11.

Vickers, S., C A Duncan, Byron H. Arison, et al.. (1983). Metabolism of the TRH analog L-pyro-2-aminoadipyl-L-histidyl-[3H]-L-thiazolidine-4-carboxamide (MK-771) in gut and brain tissue of rats: the implications for its bioavailability.. Drug Metabolism and Disposition. 11(2). 147–151. 4 indexed citations

12.

Vickers, S., C A Duncan, Byron H. Arison, et al.. (1980). The metabolic disposition of (S)-2-(3-tert-butylamino-2-hydroxypropoxy)-3-cyanopyridine in rats, dogs, and humans.. Drug Metabolism and Disposition. 8(3). 163–167. 1 indexed citations

13.

Vickers, S., et al.. (1978). EVALUATION OF SUCCINIMIDOETHYL AND PIVALOYLOXYETHYL ESTERS AS PROGENITORS OF METHYLDOPA IN MAN, RHESUS MONKEY, DOG, AND RAT. Drug Metabolism and Disposition. 6(6). 640–646. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact